{"id":"asunaprevir-asv","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asunaprevir binds to and inhibits the HCV NS3/4A serine protease, an enzyme essential for processing the HCV polyprotein into functional viral proteins. By blocking this protease activity, the drug prevents viral replication and reduces HCV viral load. It was developed as part of direct-acting antiviral (DAA) combination regimens for chronic hepatitis C infection.","oneSentence":"Asunaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:34.991Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotype 1b"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT03208322","phase":"","title":"Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-30","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03071133","phase":"","title":"Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-01-01","conditions":"Hepatitis C","enrollment":344},{"nctId":"NCT02727933","phase":"","title":"Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-03","conditions":"Hepatitis C","enrollment":1941},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT02170727","phase":"PHASE3","title":"A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06-26","conditions":"Hepatitis C Virus","enrollment":199},{"nctId":"NCT01995266","phase":"PHASE3","title":"Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02-28","conditions":"Hepatitis C","enrollment":218},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":"HCV Infection","enrollment":""},{"nctId":"NCT01492504","phase":"","title":"Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-02-07","conditions":"Hepatitis C","enrollment":1850},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03004625","phase":"PHASE3","title":"Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-11","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT02580474","phase":"PHASE4","title":"The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure","status":"COMPLETED","sponsor":"Myeong Jun Song","startDate":"2016-02","conditions":"Hepatitis C","enrollment":21},{"nctId":"NCT02762448","phase":"","title":"Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas","status":"WITHDRAWN","sponsor":"Tainan Municipal Hospital","startDate":"2016-07","conditions":"Hepatitis c","enrollment":""},{"nctId":"NCT02124044","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-02","conditions":"HIV-HCV","enrollment":30},{"nctId":"NCT02250001","phase":"","title":"Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-09-30","conditions":"Chronic Hepatitis C","enrollment":2974},{"nctId":"NCT01455090","phase":"PHASE2","title":"Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-11-30","conditions":"Chronic Hepatitis C","enrollment":320},{"nctId":"NCT02496078","phase":"PHASE3","title":"A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-08","conditions":"Hepatitis C","enrollment":207},{"nctId":"NCT02865369","phase":"","title":"Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment","status":"UNKNOWN","sponsor":"Sang Gyune Kim","startDate":"2016-09","conditions":"Chronic Hepatitis C","enrollment":103},{"nctId":"NCT01888900","phase":"PHASE2","title":"New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-05","conditions":"Cirrhosis, Chronic Hepatitis C, Hepatitis C","enrollment":35},{"nctId":"NCT02107365","phase":"PHASE2","title":"Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2013-11","conditions":"Hepatitis C Virus Genotype 4 Infection","enrollment":60},{"nctId":"NCT02292966","phase":"PHASE4","title":"Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism","status":"WITHDRAWN","sponsor":"Kirby Institute","startDate":"2015-07","conditions":"Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT01428063","phase":"PHASE2","title":"Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Hepatitis C Virus Infection","enrollment":276},{"nctId":"NCT02098616","phase":"NA","title":"Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus","status":"COMPLETED","sponsor":"Timothy Morgan, MD","startDate":"2014-07","conditions":"Hepatitis C","enrollment":25},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":18},{"nctId":"NCT02309450","phase":"PHASE2","title":"Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-12","conditions":"Hepatitis C Virus Genotype 4 Infection","enrollment":""},{"nctId":"NCT02639585","phase":"PHASE4","title":"Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-12","conditions":"Hepatitis C, Chronic","enrollment":32},{"nctId":"NCT01979939","phase":"PHASE3","title":"UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":416},{"nctId":"NCT02282709","phase":"PHASE3","title":"Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2014-02","conditions":"Chronic Hepatitis C","enrollment":12},{"nctId":"NCT01309932","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Hepatitis C","enrollment":165},{"nctId":"NCT01573351","phase":"PHASE3","title":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":398},{"nctId":"NCT01718145","phase":"PHASE3","title":"A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":"Hepatitis C Virus Infection","enrollment":258},{"nctId":"NCT01051414","phase":"PHASE2","title":"An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-04","conditions":"Hepatitis C Infection","enrollment":43},{"nctId":"NCT01030432","phase":"PHASE2","title":"Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-02","conditions":"Hepatitis C Virus","enrollment":285},{"nctId":"NCT01973049","phase":"PHASE3","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":202},{"nctId":"NCT01795911","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03","conditions":"Hepatitis C","enrollment":165},{"nctId":"NCT01497834","phase":"PHASE3","title":"A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-01","conditions":"Hepatitis C","enrollment":224},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT01012895","phase":"PHASE2","title":"Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Chronic Hepatitis C","enrollment":215},{"nctId":"NCT02123654","phase":"PHASE3","title":"UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C Virus Infection","enrollment":297},{"nctId":"NCT02323594","phase":"PHASE1","title":"A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-12","conditions":"Hepatitis C Infection","enrollment":88},{"nctId":"NCT02175602","phase":"PHASE1","title":"Study of Drug Combination on Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C Infection","enrollment":41},{"nctId":"NCT02095860","phase":"PHASE1","title":"Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT01725542","phase":"PHASE2","title":"Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-12","conditions":"HCV-HIV Co-Infection","enrollment":75},{"nctId":"NCT02103569","phase":"PHASE1","title":"Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02104843","phase":"PHASE1","title":"Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":18},{"nctId":"NCT02108639","phase":"PHASE1","title":"To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":41},{"nctId":"NCT02045966","phase":"PHASE1","title":"Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":16},{"nctId":"NCT02045693","phase":"PHASE1","title":"Drug Interaction & Methadone & Buprenorphine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01886599","phase":"PHASE1","title":"Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":"Hepatitis C","enrollment":48},{"nctId":"NCT01019070","phase":"PHASE1","title":"Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatic Insufficiency","enrollment":28},{"nctId":"NCT00722358","phase":"PHASE2","title":"A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-12","conditions":"Chronic Hepatitis C","enrollment":15},{"nctId":"NCT01063023","phase":"PHASE1","title":"Drug Interaction Oral Contraceptive Pill (OCP)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-01","conditions":"Hepatitis C Virus","enrollment":20},{"nctId":"NCT00904059","phase":"PHASE1","title":"Drug-Drug Interaction Study in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Hepatitis C","enrollment":28},{"nctId":"NCT00559247","phase":"PHASE1, PHASE2","title":"A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Chronic Hepatitis C","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":150,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-650032"],"phase":"phase_3","status":"active","brandName":"Asunaprevir (ASV)","genericName":"Asunaprevir (ASV)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Asunaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins. Used for Chronic hepatitis C virus (HCV) infection, genotype 1b.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}